RELATIVE VALUE OF TRANSDERMAL AND ORAL ESTROGEN THERAPY IN VARIOUS CLINICAL SITUATIONS

被引:21
作者
LUFKIN, EG
ORY, SJ
机构
[1] MAYO CLIN ROCHESTER, DIV INTERNAL MED, ROCHESTER, MN USA
[2] MAYO CLIN ROCHESTER, REPROD ENDOCRINOL & INFERTIL SECT, ROCHESTER, MN USA
关键词
D O I
10.1016/S0025-6196(12)61038-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: In this study, we reviewed the comparative effectiveness of transdermal and oral estrogen therapy in various groups of women. Design: On the basis of published data and personal clinical experience, we compiled recommendations for use of the various modes of estrogen replacement therapy. Material and Methods: The use of injectable estrogen or implantable estrogen pellets can no longer be recommended because of their expense, inconvenience, and unphysiologic pattern of serum estrogen response. The two main estrogen preparations currently used in the United States-orally administered conjugated estrogens and transdermally administered estradiol-undergo different metabolism, and these processes are reflected in differing levels of circulating hormones and hepatic by-products, including blood clotting factors, binding proteins, renin substrate, and apolipoproteins, and in varied composition of the bile. Results: At least theoretically, transdermal estrogen therapy might be more beneficial than oral estrogen therapy for women who smoke cigarettes or who have migraine headaches, hypertriglyceridemia, hepatobiliary disorders, fibrocystic breast disease, or a history of thromboembolism. In contrast, women with hypercholesterolemia might respond better to oral than to transdermal estrogen therapy. Conclusion: Additional properly designed clinical studies are necessary before these recommendations for estrogen replacement therapy can be validated or refuted.
引用
收藏
页码:131 / 135
页数:5
相关论文
共 47 条
[1]   INHIBITION OF CORONARY-ARTERY ATHEROSCLEROSIS BY 17-BETA ESTRADIOL IN OVARIECTOMIZED MONKEYS - LACK OF AN EFFECT OF ADDED PROGESTERONE [J].
ADAMS, MR ;
KAPLAN, JR ;
MANUCK, SB ;
KORITNIK, DR ;
PARKS, JS ;
WOLFE, MS ;
CLARKSON, TB .
ARTERIOSCLEROSIS, 1990, 10 (06) :1051-1057
[2]  
ALKJAERSIG N, 1988, J LAB CLIN MED, V111, P224
[3]  
ALVAREZ WC, 1940, P STAFF M MAYO CLIN, V15, P380
[4]   ESTROGEN AND CORONARY HEART-DISEASE IN WOMEN [J].
BARRETTCONNOR, E ;
BUSH, TL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (14) :1861-1867
[5]   POSTMENOPAUSAL ESTROGEN USE AND HEART-DISEASE RISK-FACTORS IN THE 1980S - RANCHO-BERNARDO, CALIF, REVISITED [J].
BARRETTCONNOR, E ;
WINGARD, DL ;
CRIQUI, MH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 261 (14) :2095-2100
[6]  
BIRCHER J, 1991, OXFORD TXB CLIN HEPA, V2, P1388
[7]   ESTROGENS, ARTERIAL STATUS, AND POSTMENOPAUSAL WOMEN [J].
BOURNE, T ;
HILLARD, TC ;
WHITEHEAD, MI ;
CROOK, D ;
CAMPBELL, S .
LANCET, 1990, 335 (8703) :1470-1471
[8]   CARDIOVASCULAR MORTALITY AND NONCONTRACEPTIVE USE OF ESTROGEN IN WOMEN - RESULTS FROM THE LIPID RESEARCH CLINICS PROGRAM FOLLOW-UP-STUDY [J].
BUSH, TL ;
BARRETTCONNOR, E ;
COWAN, LD ;
CRIQUI, MH ;
WALLACE, RB ;
SUCHINDRAN, CM ;
TYROLER, HA ;
RIFKIND, BM .
CIRCULATION, 1987, 75 (06) :1102-1109
[9]   EXTRASKELETAL EFFECTS OF ESTROGEN AND THE PREVENTION OF ATHEROSCLEROSIS [J].
BUSH, TL .
OSTEOPOROSIS INTERNATIONAL, 1991, 2 (01) :5-11
[10]   BIOLOGIC EFFECTS OF TRANSDERMAL ESTRADIOL [J].
CHETKOWSKI, RJ ;
MELDRUM, DR ;
STEINGOLD, KA ;
RANDLE, D ;
LU, JK ;
EGGENA, P ;
HERSHMAN, JM ;
ALKJAERSIG, NK ;
FLETCHER, AP ;
JUDD, HL .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (25) :1615-1620